Reply to "Expansion of pan-cancer mismatch repair testing: Implications for pembrolizumab eligibility and Lynch syndrome screening"
Cancer
.
2025 Jan 1;131(1):e35625.
doi: 10.1002/cncr.35625.
Epub 2024 Oct 29.
Authors
Teresa S Chai
1
,
Linda H Rodgers-Fouche
1
,
Anthony R Mattia
2
,
Daniel C Chung
1
3
Affiliations
1
Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
2
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
3
Department of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
PMID:
39470458
DOI:
10.1002/cncr.35625
No abstract available
Publication types
Letter